Increased IFN-γ synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia

Cytokines, Cellular and Molecular Therapy

Volumn 7, Issue 4, 2002, Pages 143-149

  Aswald, Jorg M ^a,b   Lipton, Jeffrey H ^a   Aswald, Sandra ^b   Messner, Hans A ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

CML; IFN ; Imatinib; Intracellular cytokine detection

Indexed keywords

BCR ABL PROTEIN; GAMMA INTERFERON; IMATINIB; PROTEIN TYROSINE KINASE; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; T-LYMPHOCYTES; TIME FACTORS;

EID: 0346150377     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: 10.1080/13684730210002319     Document Type: Article

References (51)

1. Molldrem JJ, Lee PP, Wang C et al, Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 6: 1018-23.
2. Kolb HJ, Schattenberg A, Goldman JM et al, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients [European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia]. Blood (1995) 86: 2041-50.
3. Goto S, Sato M, Kaneko R et al, Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother (1999) 48: 435-42.
4. Reuben JM, Lee BN, Johnson H et al, Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin Cancer Res (2000) 6: 1671-7.
5. Aswald JM, Lipton JH, Messner HA, Intracellular cytokine analysis of interferon-γ in T cells of patients with chronic myeloid leukemia. Cytokines Cell Mol Ther (2002) 7: 75-82.
6. Elsasser-Beile U, von Kleist S, Stahle W et al, Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer (1993) 71: 231-6.
7. Pellegrini P, Berghella AM, Del Beato T et al, Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother (1996) 42: 1-8.
8. Ito N, Nakamura H, Tanaka Y, Ohgi S, Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer (1999) 85: 2359-67.
9. Druker BJ, Lydon NB, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 105: 3-7.
10. O'Brien SG, Guilhot F, Larson RA et al, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 348: 994-1004.
11. Druker BJ, Talpaz M, Resta DJ et al, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 344: 1031-7.
12. Lucey DR, Clerici M, Shearer GM, Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 9: 532-62.
13. Collins D, Multi-system approach to analysis of T-lymphocyte activation by flow cytometry: Utilization of intracellular cytokine expression, cytokine receptor expression, and quantification of cytokine secretion as an indicator of activation. Clin Immunol (1998) 18: 140-5.
14. Filella X, Alcover J, Zarco MA et al, Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate (2000) 44: 271-4.
15. Prussin C, Metcalfe DD, Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine anti-bodies. J Immunol Methods (1995) 188: 117-28.
16. Cho EK, Heo DS, Seol JG et al, Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br J Haematol (2000) 111: 216-22.
17. Asanuma H, Sharp M, Maecker HT et al, Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 181: 859-66.
18. Mincheff M, Altankova I, Zoubak S et al, In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-γ lymphokine profile. Crit Rev Oncol Hematol (2001) 39: 125-32.
19. Rowley JD, Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243: 290-3.
20. Hochhaus A, Reiter A, Skladny H et al, Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res (1998) 144: 36-45.
21. Jung T, Schauer U, Heusser C et al, Detection of intracellular cytokines by flow cytometry. J Immunol Methods (1993) 159: 197-207.
22. Chalmers IM, Janossy G, Contreras M, Navarrete C, Intracellular cytokine profile of cord and adult blood lymphocytes. Blood (1998) 92: 11-8.
23. + T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry. Clin Exp Immunol (1996) 105: 517-22.
24. Daley GQ, Van Etten RA, Baltimore D, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247: 824-30.
25. Druker BJ, Chronic myeloid leukemia. Sceptical scientists. Lancet (2001) 358: 11.
26. Kiss TL, Abdolell M, Jamal N et al, Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol (2002) 20: 2334-43.
27. Messner HA, Bone marrow transplantation in hemopoietic malignancies. Curr Opin Oncol (1991) 3: 245-53.
28. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol (1996) 93: 606-12.
29. Romagnani S, Del Prete GF, Maggi E et al, Displacement of T lymphocytes with the 'Helper/Inducer' phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin's disease. Scand J Haematol (1983) 31: 305-14.
30. Golub SH, Rangel DM, Morton DL, In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer (1977) 20: 873-80.
31. Vose BM, Gallagher P, Moore M, Schofield PF, Specific and nonspecific lymphocyte cytotoxicity in colon carcinoma. Br J Cancer (1981) 44: 846-55.
32. Sato M, Goto S, Kaneko R et al, Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res (1998) 18: 3951-5.
33. Haanen JB, de Waal Malefijt R, Res PC et al, Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med (1991) 174: 583-92.
34. Sher A, Coffman RL, Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol (1992) 10: 385-409.
35. Yamamura M, Wang XH, Ohmen JD et al, Cytokine patterns of immunologically mediated tissue damage. J Immunol (1992) 149: 1470-5.
36. Neurath AR, Strick N, Sproul P, Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med (1992) 175: 461-9.
37. Pawelec G, Rehbein A, Schlotz E, da Silva P, Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother (1996) 42: 193-9.
38. Pawelec G, Schlotz E, Rehbein A, IFN-α regulates IL 10 production by CML cells in vitro. Cancer Immunol Immunother (1999) 48: 430-4.
39. Denizot Y, Turlure P, Bordessoule D et al, Serum IL-10 and IL-13 concentrations in patients with haematological malignancies. Cytokine (1999) 11: 634-5.
40. Norbury LC, Clark RE, Christmas SE, b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol (2000) 109: 616-21.
41. Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH, Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med (1992) 176: 1283-9.
42. Salomo M, Steinmann J, Glass B et al, Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assay. Bone Marrow Transplant (1995) 15: 179-86.
43. Bertazzoli C, Marchesi E, Passoni L et al, Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res (2000) 6: 1931-5.
44. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO, Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother (2002) 50: 588.
45. Druker BJ, Sawyers CL, Kantarjian H et al, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 344: 1038-42.
46. Gambacorti-Passerini C, Barni R, Marchesi E et al, Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol (2001) 112: 972-4.
47. Druker BJ, Tamura S, Buchdunger E et al, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2: 561-6.
48. Deininger MW, Goldman JM, Lydon N, Melo JV, The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood (1997) 90: 3691-8.
49. Gambacorti-Passerini C, le Coutre P, Mologni L et al, Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis (1997) 23: 380-94.
50. Nimmanapalli R, Porosnicu M, Nguyen D et al, Co-treatment with STI-571 enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res (2001) 7: 350-7.
51. Albert ML, Sauter B, Bhardwaj N, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392: 86-9.